5 news items
Why Travelers Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
ADPT
ADSK
ALXO
17 Apr 24
analyst Hartaj Singh maintained Viracta Therapeutics with an Outperform and maintained a $13 price target.
Spectaire Holdings Inc
BTIG Maintains Buy on Adaptive Biotechnologies, Lowers Price Target to $5
ADPT
4 Apr 24
BTIG analyst Mark Massaro maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy and lowers the price target from $6 to $5.
Adaptive Biotechnologies Names New CFO Preserves Strong Capital Position
ADPT
3 Apr 24
this structure, Adaptive preserves its strong capital position, which will bridge the MRD business to profitability and support targeted
Adaptive Biotechnologies Provides Strategic Review Update And Announces Preliminary Q1 2024 Revenue Of $41M-$43M Vs $38.21M Est.
ADPT
2 Apr 24
strong capital position which will bridge the MRD business to profitability and support targeted investments in Immune Medicine.Management
Adaptive Biotechnologies Provides Strategic Review Update and Announces Preliminary First Quarter 2024 Revenue
ADPT
2 Apr 24
strong capital position which will bridge the MRD business to profitability and support targeted investments in Immune Medicine. Management
- Prev
- 1
- Next